 Addex Therapeutics Ltd NASDAQ: ADXN has terminated the Phase 2b3 study of dipraglurant for dyskinesia associated with Parkinsons disease PD-LID due to the slow recruitment of patients. Data readout from the trial was expected in 1H of 2023. 